Patient dies in China biotech company’s gene editing trial
Though the company didn’t identify or provide details about the patient, clinical trial records suggest the study enrolled 4- to 8-year-old boys A patient with Duchenne muscular dystrophy died after receiving a gene-editing therapy in China, sparking new concerns about regulatory oversight and transparency as China seeks to cement its position as a biotechnology leader.In…